IFNA1 and neoplasm: At present, cell-based immunotherapy is a very promising therapeutic approach; incorporation of a cell-based approach that exploits the specificity of mAb-targeting can selectively deliver IFN-α into the tumor compartment, with fewer side effects as normal cells are spared.